Phase Ib/Ii Study of Ibrutinib and Venetoclax in Relapsed and Refractory Follicular Lymphoma

Hematological Oncology - United Kingdom
doi 10.1002/hon.17_2632
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

PHASE 1B STUDY OF ViPOR (VENETOCLAX, IBRUTINIB, PREDNISONE, OBINUTUZUMAB, LENALIDOMIDE) IN RELAPSED/REFRACTORY B-Cell LYMPHOMA: SAFETY, EFFICACY AND MOLECULAR ANALYSIS

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Ibrutinib as Treatment for Patients With Relapsed/Refractory Follicular Lymphoma: Results From the Open-Label, Multicenter, Phase II DAWN Study

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2018English

Polatuzumab Vedotin (Pola) + Obinutuzumab (G) + Lenalidomide (Len) in Patients (Pts) With Relapsed/Refractory (R/R) Follicular Lymphoma (Fl): Phase Ib/Ii Interim Analysis

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Safety and Activity of Ibrutinib in Combination With Durvalumab in Patients With Relapsed or Refractory Follicular Lymphoma or Diffuse Large B‐cell Lymphoma

American Journal of Hematology
Hematology
2019English

Phase 1b Study of Venetoclax-Obinutuzumab in Previously Untreated and Relapsed/Refractory Chronic Lymphocytic Leukemia

Blood
BiochemistryImmunologyCell BiologyHematology
2019English

Venetoclax (Ven) in Patients With Relapsed/Refractory Non-Hodgkin Lymphoma (Nhl)

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2017English

A Phase II Study of Carfilzomib in the Treatment of Relapsed/Refractory Mantle Cell Lymphoma

British Journal of Haematology
Hematology
2018English

The Immunologic Doublet of Lenalidomide Plus Obinutuzumab Is Highly Active in Relapsed/Refractory Follicular Lymphoma, Results of a Phase I/Ii Study

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2017English

Results From the Safety Run-In Period of the Sympatico Study Evaluating Ibrutinib in Combination With Venetoclax in Patients With Relapsed/Refractory Mantle Cell Lymphoma

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy